Clinical Trials Browser

OTHER × Neuroendocrine Tumors × lenvatinib × Clear all

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT05746208 2026-03-17

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Phase 2 Recruiting

Neuroendocrine Tumors

NCT02678780 2025-07-24

TALENT

Phase 2 Completed

123 enrolled 37 charts

Neuroendocrine Tumors